OTCMKTS:PHRRF PharmaTher (PHRRF) Stock Price, News & Analysis $0.04 0.00 (0.00%) As of 09/29/2026 03:50 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartNews and Trends About PharmaTher Stock (OTCMKTS:PHRRF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get PharmaTher alerts:Sign Up Key Stats Today's Range$0.04▼$0.0450-Day Range$0.04▼$0.0552-Week Range$0.03▼$0.29Volume7,535 shsAverage Volume160,487 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview PharmaTher Inc. is a specialty pharmaceutical company focused on developing and commercializing therapies for diseases with significant unmet medical needs. The company’s strategy centers on repurposing established medicines and advancing pharmaceutical products through clinical development and regulatory pathways. PharmaTher has primarily focused on ketamine-based treatments and psychedelic medicines. Its development programs have included potential applications of ketamine in neurological and psychiatric conditions, including status epilepticus, Parkinson’s disease and related movement disorders. The company has also pursued regulatory and commercial opportunities for pharmaceutical-grade ketamine products. PharmaTher is based in North America and has directed its activities toward the United States and Canadian pharmaceutical markets. Information about its current product portfolio and leadership may change as the company advances its development programs and strategic initiatives.AI Generated. May Contain Errors. Read More Receive PHRRF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PharmaTher and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PHRRF Stock News HeadlinesPharmaTher Holdings Ltd. (OTCMKTS:PHRRF) Shares Shorted: Short Interest Up 98.5% in SeptemberSeptember 29 at 6:20 AM | americanbankingnews.comPharmaTher Selects PD Labs, a National 503A Compounding Pharmacy, as the U.S. Center of Excellence for Its Personalized Medicine and Peptide Platform, PERSONALIZ3D(TM)August 18, 2026 | finance.yahoo.comMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 people worldwide. His system has flagged a handful of stocks worth watching ahead of September 30th. See which stocks his AI research platform is flagging right now.September 30 at 1:00 AM | TradeSmith (Ad)PharmaTher Holdings Ltd.: PharmaTher Establishes PERSONALIZ3D to Commercialize a Personalized Medicine Platform Combining Telehealth and Pharmaceutical 3D PrintingAugust 11, 2026 | finanznachrichten.deThis microcap wants to 3D print your peptidesJuly 31, 2026 | msn.comPharmaTher Holdings Ltd.: PharmaTher Collaborates with Craft Health to Evaluate CraftMake GMP-Ready Pharmaceutical 3D Printing Platform for Personalized PeptidesJuly 30, 2026 | finanznachrichten.dePharmaTher Holdings Ltd.: PharmaTher Launches Personaliz3D Peptides to Advance Personalized Peptide Care Following Positive FDA Advisory Committee RecommendationsJuly 27, 2026 | finanznachrichten.dePharmaTher Holdings Ltd.: PharmaTher Enters into Collaboration Agreement for KetaMist(R) to Advance Needle-Free Ketamine Treatment Toward FDA ApprovalJuly 21, 2026 | finanznachrichten.deSee More Headlines PHRRF Stock Analysis - Frequently Asked Questions How have PHRRF shares performed this year? PharmaTher's stock was trading at $0.0724 at the start of the year. Since then, PHRRF shares have decreased by 50.0% and is now trading at $0.0362. How do I buy shares of PharmaTher? Shares of PHRRF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolOTCMKTS:PHRRF Previous SymbolOTC:PHRRF CIKN/A Webwww.pharmather.com Phone888 846 3171FaxN/AEmployees5Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (OTCMKTS:PHRRF) was last updated on 9/30/2026 by MarketBeat.com Staff. From Our PartnersTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredThis AI Stock Reminds One Analyst of Early NvidiaJeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredI've seen this movie before (last time: 17,556%)My track record speaks for itself... KDA: 17,556%. PRE: 3,900%. OCEAN: 2,650%. Every single one was called ...Crypto 101 Media | Sponsored"How Much Can I Actually Spend Each Year With $2.5M Saved?"Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...SmartAsset | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PharmaTher Holdings Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share PharmaTher With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
